PI3K

Phosphoinositide 3-kinase

PI3K (Phosphoinositide 3-kinase), via phosphorylation of the inositol lipid phosphatidylinositol 4,5-bisphosphate ($PI(4,5)P_2$), forms the second messenger molecule phosphatidylinositol (3,4,5)-trisphosphate ($PI(3,4,5)P_3$) which recruits and activates pleckstrin homology domain containing proteins, leading to downstream signalling events crucial for proliferation, survival and migration. Class I PI3K enzymes consist of four distinct catalytic isoforms, PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ.

There are three major classes of PI3K enzymes, being class IA widely associated to cancer. Class IA PI3K are heterodimeric lipid kinases composed of a catalytic subunit (p110α, p110β, or p110δ; encoded by PIK3CA, PIK3CB, and PIK3CD genes, respectively) and a regulatory subunit (p85).

The PI3K pathway plays an important role in many biological processes, including cell cycle progression, cell growth, survival, actin rearrangement and migration, and intracellular vesicular transport.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(+)-Nortrachelogenin

(Wikstromol) Cat. No.: HY-N3171A

(+)-Nortrachelogenin (Wikstromol), a pharmacologically ligand from from wikstroemia indica, possesses antileukemic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

(Rac)-AZD 6482

((Rac)-KIN-193) Cat. No.: HY-75124

(Rac)-AZD 6482 ((Rac)-KIN-193) is the racemate of AZD 6482. AZD 6482 is a potent and selective p110β inhibitor with an IC_{50} of 0.69 nM.



Purity: 97.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(S)-PI3Kα-IN-4

Cat. No.: HY-131345A

(S)-PI3Kα-IN-4 is a potent inhibitor of **PI3Kα**, with an IC_{50} of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over **PI3Kβ**, **PI3Kδ**, and **PI3Kγ**, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

1,3-Dicaffeoylquinic acid

(1,3-O-Dicaffeoylquinic acid; 1,5-Dicaffeoylquinic acid) Cat. No.: HY-N1412

1,3-Dicaffeoylquinic acid is a caffeoylquinic acid derivative that exhibits antioxidant activity and radical scavenging activity.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

1-Deoxynojirimycin

(Duvoglustat) Cat. No.: HY-14860

1-Deoxynojirimycin (Duvoglustat) is a potent and orally active **α-glucosidase** inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

1-Deoxynojirimycin hydrochloride

(Duvoglustat hydrochloride) Cat. No.: HY-14860A

1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active **α-glucosidase** inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

25(R,S)-Ruscogenin

Cat. No.: HY-N5136

Ruscogenin suppresses HCC metastasis by reducing the expression of MMP-2, MMP-9, uPA, VEGF and HIF-1α via regulating the **PI3K/Akt/mTOR** signaling pathway. And Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by su.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

3-Methyladenine

(3-MA) Cat. No.: HY-19312

3-Methyladenine (3-MA) is a **PI3K** inhibitor. 3-Methyladenine is a widely used inhibitor of **autophagy** via its inhibitory effect on class III PI3K.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 200 mg, 500 mg

740 Y-P

(740YPDGFR; PDGFR 740Y-P) Cat. No.: HY-P0175

740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable **PI3K** activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone.

Purity: 99.67%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

740 Y-P TFA

(740YPDGFR TFA; PDGFR 740Y-P TFA) Cat. No.: HY-P0175A

740 Y-P TFA is a potent and cell-permeable **PI3K** activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A66

Cat. No.: HY-13261

A66 is a highly specific and selective **p110α** inhibitor with an **IC_{50}** of 32 nM.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Acalisib

(GS-9820; CAL-120)

Cat. No.: HY-12644

Acalisib is a potent and selective **PI3Kδ** inhibitor with an **IC_{50}** of 12.7 nM.



Purity: 99.98%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ACT001

Cat. No.: HY-128861A

ACT001 is an orally active **PAI-1** inhibitor by inhibiting the phosphorylation of **PI3K** and **AKT**. ACT001 inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to **STAT3**.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Alpelisib

(BYL-719)

Cat. No.: HY-15244

Alpelisib (BYL-719) is a potent, selective, and orally active **PI3Kα** inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC_{50}s of 5/250/290/1200 nM, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alpelisib hydrochloride

(BYL-719 hydrochloride)

Cat. No.: HY-15244A

Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective **PI3Kα** inhibitor with **IC_{50}**s of 5 nM, 250 nM, 290 nM and 1200 nM for **p110α**, **p110γ**, **p110δ**, and **p110β**, respectively. Alpelisib hydrochloride (BYL-719 hydrochloride) shows antineoplastic activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Amdizalisib

(HMPL-689)

Cat. No.: HY-132807

Amdizalisib (HMPL-689) is a **PI3K** inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMG 511

Cat. No.: HY-13440

AMG 511 is a potent and orally available pan inhibitor of class I **PI3K**s, with **K_i**s of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

AMG319

Cat. No.: HY-12948

AMG319 is a potent and selective **PI3Kδ** kinase inhibitor with **IC_{50}** of 18 nM.



Purity: 98.27%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apitolisib

(GDC-0980; GNE 390; RG 7422)

Cat. No.: HY-13246

Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I **PI3** kinase and **mTOR kinase** (**TORC1/2**) inhibitor with **IC_{50}**s of 5 nM/27 nM/7 nM/14 nM for **PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ**, and with a **K_i** of 17 nM for **mTOR**.



Purity: 98.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AQX-016A

Cat. No.: HY-115620

AQX-016A is an orally active and potent **SHIP1** agonist. AQX-016A can activate recombinant **SHIP1** enzyme in vitro and stimulate **SHIP1** activity. AQX-016A also can inhibit the **PI3K** pathway and TNFa production, can be useful for various inflammatory diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arnicolide D

Cat. No.: HY-N6843

Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the **caspase** signaling pathway and inhibits the **PI3K/AKT/mTOR** and **STAT3** signaling pathways.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS-041164

Cat. No.: HY-118521

AS-041164 is a potent, selective and orally active **PI3Kγ** isoform inhibitor with an IC_{50} of 70 nM. AS-041164 shows less activity against PI3Kα, PI3Kβ, and PI3Kδ (IC_{50}s of 240 nM, 1.45 μM, and 1.70 μM, respectively). AS-041164 has anti-inflammatory effects.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS-252424

Cat. No.: HY-13532

AS-252424 is a potent and selective **PI3Kγ** inhibitor with an IC_{50} of 30±10 nM.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

AS-604850

Cat. No.: HY-13531

AS-604850 is a potent, selective and ATP-competitive **PI3Kγ** inhibitor with an IC_{50} value of 0.25 μM and a K_i value of 0.18 μM. AS-604850 shows isoform selective inhibitor of **PI3Kγ** with over 30-fold selectivity for PI3Kδ and β, and 18-fold selectivity over PI3Kα, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS-605240

Cat. No.: HY-10109

AS-605240 is a specific and orally active inhibitor of the **PI3Kγ**, with an IC_{50} of 8 nM, and a K_i of 7.8 nM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Autophinib

Cat. No.: HY-101920

Autophinib is a potent, selective **autophagy** inhibitor with IC_{50}s of 90 nM and 40 nM for starvation- and Rapamycin-induced **autophagy**, respectively. Autophinib is also an ATP competitive **Vacuolar Protein Sorting 34 (VPS34)** inhibitor with an IC_{50} of 19 nM.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

AZ2

Cat. No.: HY-111570

AZ2 is a highly selective **PI3Kγ** inhibitor (The **pIC$_{50}$** value for **PI3Kγ** is 9.3). AZ2 can be used for the research of inflammatory and immune diseases.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD 6482

(KIN-193)

Cat. No.: HY-10344

AZD 6482 (KIN-193) is a potent and selective **p110β** inhibitor with an IC_{50} of 0.69 nM.



Purity: 99.56%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD-8835

Cat. No.: HY-12869

AZD8835 is a potent and selective inhibitor of **PI3Kα** and **PI3Kδ** with IC_{50}s of 6.2 and 5.7 nM, respectively.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD3458

Cat. No.: HY-112443

AZD3458 is a potent and remarkably selective **PI3Kγ** inhibitor with **pIC$_{50}$**s of 9.1, 5.1, <4.5, and 6.5 for **PI3Kγ**, **PI3Kα**, **PI3Kβ**, and **PI3Kδ**, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD8154

Cat. No.: HY-115870

AZD8154 is a novel inhaled selective **PI3Kγδ** dual inhibitor targeting airway inflammatory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD8186

Cat. No.: HY-12330

AZD8186 is a **PI3K** inhibitor, which potently inhibits PI3Kβ (IC_{50}=4 nM) and PI3Kδ ($IC50_{50}$=12 nM) with selectivity over PI3Kα (IC_{50}=35 nM) and PI3Kγ (IC_{50}=675 nM).



Purity: 99.97%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY1082439

Cat. No.: HY-100886

BAY1082439 is an orally bioavailable, selective **PI3Kα/β/δ** inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BEBT-908

(PI3Kα inhibitor 1)

Cat. No.: HY-19763

BEBT-908 (PI3Kα inhibitor 1) is a selective **PI3Kα** inhibitor extracted from patent US/20120088764A1, Compound 243, has an IC_{50}<0.1 μM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 μM≤IC_{50}≤1 μM) .



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BGT226

(NVP-BGT226)

Cat. No.: HY-13334A

BGT226 (NVP-BGT226) is a **PI3K** (with IC_{50}s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**)/**mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

BGT226 maleate

(NVP-BGT226 maleate)

Cat. No.: HY-13334

BGT226 (NVP-BGT226 maleate) is a **PI3K** (with IC_{50}s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**) /**mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bimiralisib

(PQR309)

Cat. No.: HY-12868

Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I **PI3K/mTOR** inhibitor with IC_{50}s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ**, **PI3Kγ** and **mTOR**, respectively. Bimiralisib is an **mTORC1** and **mTORC2** inhibitor.



Purity: 98.74%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Brevianamide F

(Cyclo(L-Pro-L-Trp))

Cat. No.: HY-100385

Brevianamide F (Cyclo(L-Pro-L-Trp)) is a mycotoxin isolated from Colletotrichum gloeosporioides, with antibacterial activity. Brevianamide F shows potent **PI3Kα** inhibitory activity with an IC_{50} of 4.8 μM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Buparlisib

(BKM120; NVP-BKM120)

Cat. No.: HY-70063

Buparlisib (BKM120; NVP-BKM120) is a pan-class I **PI3K** inhibitor, with IC_{50}s of 52, 166, 116 and 262 nM for **p110α**, **p110β**, **p110δ** and **p110γ**, respectively.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Buparlisib Hydrochloride

(BKM120 Hydrochloride; NVP-BKM120 Hydrochloride)

Cat. No.: HY-15180

Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I **PI3K** inhibitor, with IC_{50} of 52 nM/166 nM/116 nM/262 nM for **p110α/p110β/p110δ/p110γ**, respectively.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CAL-130

Cat. No.: HY-16122A

CAL-130 is a **PI3Kδ** and **PI3Kγ** inhibitor with IC_{50}s of 1.3 and 6.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAL-130 Hydrochloride

Cat. No.: HY-16122B

CAL-130 is a **PI3Kδ** and **PI3Kγ** inhibitor with IC_{50}s of 1.3 and 6.1 nM, respectively.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CAL-130 Racemate

Cat. No.: HY-16122

CAL-130 Racemate is the racemate of CAL-130. CAL-130 Racemate is a **PI3Kδ** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10505

Cat. No.: HY-13530

CAY10505 is a potent and selective **PI3Kγ** inhibitor with an IC_{50} of 30 nM in neurons.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

CGS 15943

Cat. No.: HY-100678

CGS 15943 is an orally bioavailable non-xanthine **Adenosine Receptor** antagonist. Its K_i for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM in transfected CHO cells, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg

CH5132799

Cat. No.: HY-15466

CH5132799 is a selective class I **PI3K** inhibitor. CH5132799 inhibits class I PI3Ks, particularly PI3Kα, with an IC_{50} of 14 nM.



Purity: 98.81%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chaetominine

((-)-Chaetominine)

Cat. No.: HY-125136

Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-PI3KD-317

Cat. No.: HY-112608

CHMFL-PI3KD-317 is a highly potent, selective and orally active **PI3Kδ** inhibitor, with an IC_{50} of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC_{50}, 62.6 nM), PI3Kβ (IC_{50}, 284 nM), PI3Kγ (IC_{50}, 202.7 nM),...



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CNX-1351

Cat. No.: HY-16596

CNX-1351 is a potent and isoform-selective targeted covalent **PI3Kα** inhibitor with IC_{50} of 6.8 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Copanlisib

(BAY 80-6946)

Cat. No.: HY-15346

Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I **PI3K** inhibitor, with IC_{50}s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ** and **PI3Kγ**, respectively.



Purity: 99.50%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Copanlisib dihydrochloride

(BAY 80-6946 dihydrochloride) Cat. No.: HY-15346A

Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I **PI3K** inhibitor, with **IC_{50}**s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ** and **PI3Kγ**, respectively.



Purity: 99.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Copanlisib-d6

(BAY 80-6946-d6) Cat. No.: HY-15346S1

Copanlisib-d6 (BAY 80-6946-d6) is the deuterium labeled Copanlisib. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I **PI3K** inhibitor, with **IC_{50}**s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ** and **PI3Kγ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Copanlisib-d8

(BAY 80-6946-d8) Cat. No.: HY-15346S

Copanlisib-d8 (BAY 80-6946-d8) is the deuterium labeled Copanlisib. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I **PI3K** inhibitor, with **IC_{50}**s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ** and **PI3Kγ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CYH33

Cat. No.: HY-123938

CYH33 is an orally active, highly selective **PI3Kα** inhibitor with **IC_{50}**s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

CYH33 methanesulfonate

Cat. No.: HY-123938A

CYH33 methanesulfonate is an orally active, highly selective **PI3Kα** inhibitor with **IC_{50}**s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CZC24832

Cat. No.: HY-15294

CZC24832 is a highly selective and potent **PI3Kγ** inhibitor (IC_{50}=27 nM) with apparent dissociation constants (**K_d^{app}**) of 19 nM.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dactolisib

(BEZ235; NVP-BEZ235) Cat. No.: HY-50673

Dactolisib (BEZ235) is an orally active and dual pan-class I **PI3K** and **mTOR** kinase inhibitor with **IC_{50}**s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for **p110α/p110γ/p110δ/p110β** and **mTOR**, respectively. Dactolisib (BEZ235) inhibits both **mTORC1** and **mTORC2**.



Purity: 99.94%
Clinical Data: Phase 3
Size: 50 mg, 100 mg, 200 mg, 500 mg

Dactolisib Tosylate

(BEZ235 Tosylate; NVP-BEZ 235 Tosylate) Cat. No.: HY-15174

Dactolisib Tosylate (BEZ235 Tosylate) is a dual **PI3K** and **mTOR** kinase inhibitor with **IC_{50}** values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits **mTORC1** and **mTORC2**.



Purity: 99.88%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Desmethyl-VS-5584

(Desmethyl-SB2343) Cat. No.: HY-101776

Desmethyl-VS-5584 is a dimethyl analog of VS-5584 which is an potent and selective **mTOR/PI3K** dual inhibitor with pyrido [2,3-d] pyrimidine structure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desmethylglycitein

(4',6,7-Trihydroxyisoflavone) Cat. No.: HY-N5072

Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dezapelisib

(INCB040093) Cat. No.: HY-109029

Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (**PI3Kδ**). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Disitertide

(P144) Cat. No.: HY-P0118

Disitertide (P144) is a peptidic **transforming growth factor-beta 1 (TGF-β1)** inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a **PI3K** inhibitor and an **apoptosis** inducer.
.

TSLDASIIWAMMQN

Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Disitertide TFA

(P144 TFA) Cat. No.: HY-P0118A

Disitertide (P144) TFA is a peptidic **transforming growth factor-beta 1 (TGF-β1)** inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) TFA is also a **PI3K** inhibitor and an **apoptosis** inducer.
.

TSLDASIIWAMMQN (TFA salt)

Purity: 95.87%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DS-7423

Cat. No.: HY-124036

DS-7423 is a dual **PI3K** and **mTOR** inhibitor, with IC_{50} values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Duvelisib

(IPI-145; INK1197) Cat. No.: HY-17044

Duvelisib (IPI-145) is a selectivite **p100δ** inhibitor with IC_{50} of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Duvelisib (R enantiomer)

(IPI-145 R enantiomer; INK1197 R enantiomer) Cat. No.: HY-17044A

Duvelisib R enantiomer is a **PI3K** inhibitor, which is the less active enantiomer of Duvelisib.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Duvelisib-d5

(IPI-145-d5; INK1197-d5) Cat. No.: HY-17044S

Duvelisib-d5 (IPI-145-d5) is the deuterium labeled Duvelisib. Duvelisib (IPI-145) is a selectivite **p100δ** inhibitor with IC_{50} of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Eganelisib

(IPI-549) Cat. No.: HY-100716

Eganelisib (IPI549) is a potent and selective **PI3Kγ** inhibitor with an IC_{50} of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases.



Purity: 99.65%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Erucic acid

Cat. No.: HY-N7109

Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Esculetin

Cat. No.: HY-N0284

Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of **PI3K/Akt** pathway.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

ETP-45658

Cat. No.: HY-110109

ETP-45658 is a potent **PI3K** inhibitor, with IC_{50}s of 22.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ** and **PI3Kγ**, respectively. ETP-45658 also can inhibit **DNA-PK** (IC_{50}=70.6 nM) and **mTOR** (IC_{50}=152.0 nM). ETP-45658 can be used for the research of cancer.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ETP-46321

Cat. No.: HY-12340

ETP-46321 is a potent and orally bioavailable **PI3Kα** and **PI3Kδ** inhibitor with K_{iapp}s of 2.3 and 14.2 nM, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ETP-47037

Cat. No.: HY-139810

ETP-47037 is a potent and inhibitor of **PI3Kα** isoform with an IC_{50} value of 0.99 nM. ETP-47037 also inhibits the PI3Kβ, PI3Kδ, and PI3Kγ isoforms, with IC_{50} values of 49.2, 7.13, and 49.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Euscaphic acid

Cat. No.: HY-N2566

Euscaphic acid, a **DNA polymerase** inhibitor, is a triterpene from the root of the R. alceaefolius Poir. Euscaphic inhibits calf DNA polymerase α (pol α) and rat DNA polymerase β (pol β) with IC_{50} values of 61 and 108 μM. Euscaphic acid induces **apoptosis**.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

FD223

Cat. No.: HY-132231

FD223 is a potent and selective phosphoinositide 3-kinase delta **(PI3Kδ)** inhibitor. FD223 displays high potency (IC_{50}=1 nM) and good selectivity over other isoforms (IC_{50}s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ).



Purity: 98.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fimepinostat

(CUDC-907)

Cat. No.: HY-13522

Fimepinostat (CUDC-907) potently inhibits class I **PI3Ks** as well as classes I and II **HDAC** enzymes with an IC_{50} of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ganoderic acid DM

Cat. No.: HY-120140

Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GDC-0326

Cat. No.: HY-101272

GDC-0326 is a potent and selective **PI3Kα** inhibitor with a K_i of 0.2 nM.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gedatolisib

(PKI-587; PF-05212384)

Cat. No.: HY-10681

Gedatolisib (PKI-587) is a highly potent dual inhibitor of **PI3Kα**, **PI3Kγ**, and **mTOR** with IC_{50}s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Gedatolisib is equally effective in both complexes of mTOR, **mTORC1** and **mTORC2**.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilmelisib

Cat. No.: HY-139412

Gilmelisib is an antineoplastic. Gilmelisib is a **PI3K** inhibitor (IC_{50} <1 nM for PI3K p110α) extracted from WO2017101847 A1, compound 1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rk1

Cat. No.: HY-N2515

Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of **Jak2/Stat3** signaling pathway and **NF-κB**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Glaucocalyxin A

Cat. No.: HY-N2112

Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating **PI3K/Akt** signaling pathway. Glaucocalyxin A has antitumor effect.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GNE-317

Cat. No.: HY-12763

GNE-317 is a **PI3K/mTOR** inhibitor, is able to cross the blood-brain barrier (BBB).



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-477

Cat. No.: HY-11042

GNE-477 is a potent and efficacious dual **PI3K** (IC_{50}=4 nM)/**mTOR**(K_i=21 nM) inhibitor.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GNE-490

Cat. No.: HY-10812

GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-**PI3K** inhibitor with IC_{50}s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC_{50}=750 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE-493

Cat. No.: HY-10811

GNE-493 is a potent, selective, and orally available dual **pan-PI3-kinase/mTOR** inhibitor with IC_{50}s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GS-9901

Cat. No.: HY-100694

GS-9901 is a highly selective and orally active **PI3Kδ** inhibitor, with an IC_{50} of 1 nM. Has potential to treat rheumatoid arthritis.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

GSK1059615

Cat. No.: HY-12036

GSK1059615 is a dual inhibitor of **PI3Kα/β/δ/γ** (reversible) and **mTOR** with IC_{50} of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2292767

Cat. No.: HY-15280

GSK2292767 is a potent and selective inhibitor of **PI3Kδ**, with a pIC_{50} of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

GSK251

Cat. No.: HY-132880

GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of **PI3Kδ** with a novel binding mode.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2636771

Cat. No.: HY-15245

GSK2636771 is a potent, selective and orally bioavailable inhibitor of **PI3Kβ** with a K_i of 0.89 nM and an IC_{50} of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.



Purity: 99.86%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hederacolchiside A1

Cat. No.: HY-N6950

Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating **PI3K/Akt/mTOR** signaling pathway.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Heterophyllin B

Cat. No.: HY-N1476

Heterophyllin B is an active cyclic peptide isolated from Pseudostellaria heterophylla. Heterophyllin B provides a novel strategy for the treatment of esophageal cancer.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Hirsutenone

Cat. No.: HY-N4042

Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HS-173

Cat. No.: HY-15868

HS-173 is a novel **PI3K** inhibitor, that is used for cancer treatment.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

hSMG-1 inhibitor 11e

Cat. No.: HY-124760

hSMG-1 inhibitor 11e is a potent and selective **hSMG-1 kinase** inhibitor with an IC_{50} of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC_{50} of 45 nM), PI3Kα/γ (IC_{50}s of 61 nM and 92 nM) and CDK1/CDK2 (IC_{50}s of 32 μM and 7.1 μM).



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

hSMG-1 inhibitor 11j

Cat. No.: HY-124719

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of **hSMG-1**, with an IC_{50} of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over **mTOR** (IC_{50}=50 nM), **PI3Kα/γ** (IC_{50}=92/60 nM) and **CDK1/CDK2** (IC_{50}=32/7.1 μM).



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

IC-87114

Cat. No.: HY-10110

IC-87114 is a potent and selective **PI3Kδ** inhibitor with IC_{50} of 0.5 μM.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Idelalisib

(CAL-101; GS-1101)

Cat. No.: HY-13026

Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable **p110δ** inhibitor with an IC_{50} of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Idelalisib D5

(CAL-101 D5; GS-1101 D5)

Cat. No.: HY-13026S

Idelalisib D5 is a deuterium labeled Idelalisib. Idelalisib is a highly selective and orally bioavailable p110δ inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

IHMT-PI3Kδ-372

Cat. No.: HY-131910

IHMT-PI3Kδ-372 is a potent and selective **PI3Kδ** inhibitor with an IC_{50} of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (5683 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IITZ-01

Cat. No.: HY-112897

IITZ-01 is a potent lysosomotropic **autophagy** inhibitor with single-agent antitumor activity, with an IC_{50} of 2.62 μM for PI3Kγ.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

iMDK

Cat. No.: HY-110171

iMDK is a potent **PI3K** inhibitor and inhibits the growth factor **MDK** (also known as **midkine** or MK). iMDK suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

iMDK quarterhydrate

Cat. No.: HY-110171A

iMDK quarterhydrate is a potent **PI3K** inhibitor and inhibits the growth factor **MDK** (also known as **midkine** or MK). iMDK quarterhydrate suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

Inavolisib

(GDC-0077; RG6114)

Cat. No.: HY-101562

GDC-0077 (RG6114) is a potent, orally available, and selective **PI3Kα** inhibitor (IC_{50}=0.038 nM). GDC-0077 (RG6114) exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.



Purity: 98.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IPI-3063

Cat. No.: HY-111510

IPI-3063 is a potent and selective **PI3K p110δ** inhibitor with an IC_{50} of 2.5±1.2 nM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Isorhamnetin

(3'-Methylquercetin)

Cat. No.: HY-N0776

Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Isorhamnetin-d3

(3'-Methylquercetin-d3)

Cat. No.: HY-N0776S

Isorhamnetin-d3 (3'-Methylquercetin-d3) is the deuterium labeled Isorhamnetin. Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KP372-1

Cat. No.: HY-15673

KP372-1, an **Akt** inhibitor, block signalling through the PI3K pathway and inhibit cell proliferation while inducing apoptosis of cancer cells.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

KU-0060648

Cat. No.: HY-13431

KU-0060648 is a dual inhibitor of **PI3K** and **DNA-PK** with IC_{50}s of 4 nM, 0.5 nM, 0.1 nM, 0.594 nM and 8.6 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and DNA-PK, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg

LAS191954

Cat. No.: HY-101114

LAS191954 is a potent, selective and orally active **PI3Kδ** inhibitor for inflammatory diseases treatment, with an IC_{50} of 2.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leniolisib
(CDZ173)

Cat. No.: HY-17635

Leniolisib (CDZ173) is a potent and selective **PI3Kδ** inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.



Purity: 99.25%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Linperlisib
(YY-20394)

Cat. No.: HY-102031

Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of **PI3Kδ** extracted from patent WO 2015055071 A1, compound 10; has an IC_{50} of 6.4 nM.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LX2343

Cat. No.: HY-111383

LX2343 is a **BACE1** enzyme inhibitor with an IC_{50} value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive **PI3K** inhibitor with an IC_{50} of 15.99±3.23 μM. LX2343 stimulates **autophagy** in its promotion of **Aβ** clearance.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY294002

Cat. No.: HY-10108

LY294002 is a broad-spectrum inhibitor of **PI3K** with IC_{50}s of 0.5, 0.57, and 0.97 μM for **PI3Kα**, **PI3Kδ** and **PI3Kβ**, respectively. LY294002 also inhibits **CK2** with an IC_{50} of 98 nM.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

MCX 28

Cat. No.: HY-139832

MCX 28, a triple **PI3K/mTOR/PIM** inhibitor, displays low nanomolar activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MSC2360844

Cat. No.: HY-135827

MSC2360844 is a potent, orally active and selective **PI3Kδ** inhibitor, with an IC_{50} of 145 nM. MSC2360844 shows highly selective against a panel of 278 additional kinases.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSC2360844 hemifumarate

Cat. No.: HY-135827A

MSC2360844 hemifumarate is a potent, orally active and selective **PI3Kδ** inhibitor, with an IC_{50} of 145 nM. MSC2360844 hemifumarate shows highly selective against a panel of 278 additional kinases.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MTX-211

Cat. No.: HY-107364

MTX-211 is a dual inhibitor of **EGFR** and **PI3K**, used for the treatment of cancer and other diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mytoxin B

Cat. No.: HY-131055

Mytoxin B is an **ADC cytotoxin**. Mytoxin B is a satratoxin-type trichothecene macrolide and is similar to the effect of LY294002 (HY-10108). Mytoxin B induces cell **apoptosis** via PI3K/Akt pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nemiralisib

(GSK2269557 (free base))

Cat. No.: HY-19535A

Nemiralisib (GSK2269557 free base) is a potent and highly selective **PI3Kδ** inhibitor with a **pK$_i$** of 9.9.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NIBR-17

Cat. No.: HY-18310

NIBR-17 is a pan-class I **PI3K** inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC781406

Cat. No.: HY-100470

NSC781406 is a highly potent **PI3K** and **mTOR** inhibitor with an **IC$_{50}$** of 2 nM for PI3Kα.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BAG956

(BAG 956)

Cat. No.: HY-13333

NVP-BAG956 is an ATP-competitive **PI3K** inhibitor with **IC50**s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVP-CLR457

Cat. No.: HY-146260

NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I **PI3K** inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-QAV-572

Cat. No.: HY-16355

NVP-QAV-572 is a **PI3K** inhibitor extracted from patent US7998990B2, Compound Example 8, has an **IC$_{50}$** of 10 nM.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVS-PI3-4

Cat. No.: HY-133907

NVS-PI3-4 is a specific **PI3Kγ** inhibitor. NVS-PI3-4 can be used for the research of allergies, inflammatory and cancer diseases.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Omipalisib

(GSK2126458; GSK458)

Cat. No.: HY-10297

Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of **PI3K** with **K$_i$**s of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity.



Purity: 99.93%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ON 146040

Cat. No.: HY-12338

ON 146040 is a potent **PI3Kα** and **PI3Kδ** (**IC$_{50}$**≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits **Abl1** (**IC$_{50}$**<150 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Orobol

Cat. No.: HY-N3127

Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits **CK1ε**, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC$_{50}$=1.24-4.45 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Oroxin B

Cat. No.: HY-N1435

Oroxin B (OB) is a flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

P110δ-IN-1

Cat. No.: HY-114428

P110δ-IN-1 is a potent and selective inhibitor of **P110δ** extracted from patent WO 2014055647 A1, with an IC_{50} of 8.4 nM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PARP/PI3K-IN-1

Cat. No.: HY-133124

PARP/PI3K-IN-1 (compound 15) is a potent **PARP/PI3K** inhibitor with **pIC$_{50}$** values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Parsaclisib

(INCB050465)

Cat. No.: HY-109068

Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of **PI3Kδ**, with an IC_{50} of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms.



Purity: 99.31%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Parsaclisib hydrochloride

(INCB050465 hydrochloride)

Cat. No.: HY-109068A

Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of **PI3Kδ**, with an IC_{50} of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-04691502

Cat. No.: HY-15177

PF-04691502 is a potent and selective inhibitor of **PI3K** and **mTOR**. PF-04691502 binds to human PI3Kα, β, δ, γ and mTOR with K_is of 1.8, 2.1, 1.6, 1.9 and 16 nM, respectively.



Purity: 99.64%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-04979064

Cat. No.: HY-100398

PF-04979064 is a potent and selective **PI3K/mTOR** dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PF-06843195

Cat. No.: HY-131972

PF-06843195 is a highly selective **PI3Kα** inhibitor with an IC_{50} of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for **PI3Kα** and **PI3Kδ** in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-4989216

Cat. No.: HY-13864

PF-4989216 is a potent and selective **PI3Kα** inhibitor with a K_i of 0.6 nM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-103

Cat. No.: HY-10115

PI-103 is a potent **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM. PI-103 induces **autophagy**.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-103 Hydrochloride

Cat. No.: HY-10115A

PI-103 Hydrochloride is a dual **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 Hydrochloride also inhibits **DNA-PK** with an **IC50** of 2 nM. PI-103 Hydrochloride induces **autophagy**.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-103-d8

Cat. No.: HY-10115S

PI-103-d8 is the deuterium labeled PI-103. PI-103 is a potent **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM. PI-103 induces **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI-3065

Cat. No.: HY-12235

PI-3065 is a potent inhibitor of **PI3K p110δ**, with IC_{50} and K_i values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC_{50}s of 910, 600, >10000 nM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-828

Cat. No.: HY-108606

PI-828 is a dual **PI3K** and **casein kinase 2** (**CK2**) inhibitor with IC_{50}s of 173 nM, 149 nM, and 1127 nM for **p110α**, **CK2**, and **CK2α2** in lipid kinase assay, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PI3K-IN-1

(XL-147 derivative 1)

Cat. No.: HY-12068

PI3K-IN-1 (XL-147 derivative 1) is a potent inhibitor of **PI3K**. PI3K-IN-1 (25 μM) blocks PI3K/Akt signaling pathways.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PI3K-IN-10

Cat. No.: HY-112191

PI3K-IN-10 is a potent pan-**PI3K** inhibitor as a benzimidazole derivative, compound 332, extracted from patent WO2018057808A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-19 hydrochloride

Cat. No.: HY-141690A

PI3K-IN-19 hydrochloride is a phosphotidylinositol-3-kinase (**PI3K**) inhibitor extracted from patent WO2017153220, step 5.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-2

Cat. No.: HY-101517

PI3K-IN-2 (compound 10) is a potent and orally active **PI3Kβ/δ** (IC_{50}=7.1/8.6 nM) inhibitor with excellent selectivity versus PI3Kσ and PI3Kγ (IC_{50}=13/190 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-22

Cat. No.: HY-10620

PI3K-IN-22 is a **PI3Kα/mTOR** dual kinase inhibitor. PI3K-IN-22 has IC_{50}s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-23

Cat. No.: HY-132898

PI3K-IN-23 is an (E)-9-oxooctadec-10-en-12-ynoic acid analogue to promote glucose uptake with an EC_{50} value of 7.00 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-26

Cat. No.: HY-142676

PI3K-IN-26 is a potent **PI3K** inhibitor with an IC_{50} of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-27

Cat. No.: HY-142677

PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-29

Cat. No.: HY-144450

PI3K-IN-29 is a potent **PI3K** inhibitor. PI3K-IN-29 displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC_{50} values of 0.264, 2.04 and 1.14 μM, respectively. PI3K-IN-29 inhibits **PI3K/Akt** pathway by inhibiting phosphorylation of **Akt** that is catalyzed by **PI3K**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-30

Cat. No.: HY-143404

PI3K-IN-30 (compound 6d) is a potent **PI3K** inhibitor with **IC_{50}**s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-31

Cat. No.: HY-143403

PI3K-IN-31 (Compound 6b) is a potent **PI3K** inhibitor with **IC_{50}**s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for **PI3Kα**, **PI3Kβ**, **PI3Kγ**, and **PI3Kδ**, respectively. PI3K-IN-31 has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-6

Cat. No.: HY-101115

PI3K-IN-6 (compound 20a) is an oral active and highly selective **phosphoinositide 3-kinase (PI3K) β/δ** inhibitor, with **IC_{50}** values of 7.8 nM/5.3 nM for PI3K β/δ, respectively. PI3K-IN-6 (compound 20a) has potential top treat phosphatase and tensin homolog (PTEN) feficient tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-9

Cat. No.: HY-133029

PI3K-IN-9 (compound 1-14) is a potent and selective **PI3Kδ** inhibitor with an **IC_{50}** of 8.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/AKT-IN-1

Cat. No.: HY-144806

PI3K/AKT-IN-1 is an effective **PI3K/AKT** dual inhibitor (**IC_{50}** of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/Akt/mTOR-IN-2

Cat. No.: HY-146751

PI3K/Akt/mTOR-IN-2 is a **PI3K/AKT/mTOR** pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with **IC_{50}** value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/HDAC-IN-1

Cat. No.: HY-128582

PI3K/HDAC-IN-1 is a potent dual inhibitor of **PI3K/HDAC**, potently inhibits PI3Kδ and HDAC1 with **IC_{50}**s of 8.1 nM and 1.4 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/mTOR Inhibitor-1

Cat. No.: HY-112602

PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual **PI3K/mTOR** inhibitor with IC_{50}s of 20/376/204/46 nM and 186 nM for **PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ** and **mTOR**, respectively. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/mTOR Inhibitor-2

Cat. No.: HY-111508

PI3K/mTOR Inhibitor-2 is a potent dual pan-**PI3K/mTOR** inhibitor with IC_{50}s of 3.4/34/16/1 nM for **PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ** and 4.7 nM for **mTOR**. Antitumor activity.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI3K/mTOR Inhibitor-3

Cat. No.: HY-141476

PI3K/mTOR Inhibitor-3 (compound 12), an imidazoline, is a potent **PI3K** and **mTOR** dual inhibitor. PI3K/mTOR Inhibitor-3 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/mTOR Inhibitor-5

Cat. No.: HY-146016

PI3K/mTOR Inhibitor-5 (compound 19a) is a potent and dual **PI3K** and **mTOR** inhibitor, with IC_{50} values of 86.9 nM and 14.6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Ka-IN-5

Cat. No.: HY-144295

PI3Ka-IN-5 (compound 6 ab) is a potent **PI3Kα/mTOR** inhibitor, with an IC_{50} of 0.7 nM and 3.3 nM, respectively. PI3Ka-IN-5 can be used for the research of colorectal cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kdelta inhibitor 1

Cat. No.: HY-112439

PI3Kdelta inhibitor 1 (Compound 5d) is a potent, selective and orally available **PI3Kδ** inhibitor with an IC_{50} of 1.3 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kα-IN-4

Cat. No.: HY-131345

PI3Kα-IN-4 is a potent, selective and orally active inhibitor of **PI3Kα**, with an IC_{50} of 1.8 nM. PI3Kα-IN-4 has antitumor activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PI3Kα-IN-5

Cat. No.: HY-144829

PI3Kα-IN-5 (Compound 6ab) is a potent **PI3Kα** inhibitor with an IC_{50} of 0.7 nM. PI3Kα-IN-5 shows antitumor activity with good metabolic stabilities and safety profiles.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kα/mTOR-IN-1

Cat. No.: HY-U00326

PI3Kα/mTOR-IN-1 is a potent PI3Kα/mTOR dual inhibitor, with an IC_{50} of 7 nM for PI3Kα in a cell assay, and K_is of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kβ-IN-1

Cat. No.: HY-145338

PI3Kβ-IN-1 (compound (P)-14) is a selective and orally active **PI3Kβ** inhibitor, with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kγ inhibitor 1

Cat. No.: HY-10549

PI3Kγ inhibitor 1 is a **PI3Kδ** and **PI3Kγ** inhibitor extracted from patent WO2014004470A1, Compound 168 in Table 4, has IC_{50}s of <100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kγ inhibitor 2

Cat. No.: HY-112286

PI3Kγ inhibitor 2 (Compound 16) is an orally bioavailable, CNS-penetrant, isoform selective **PI3Kγ** inhibitor with a K_i of 4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kγ inhibitor 4

Cat. No.: HY-132299

PI3Kγ inhibitor 4 is a potent, selective and orally active inhibitor of **PI3Kγ**, with an IC_{50} of 40 nM. PI3Kγ inhibitor 4 shows 7, 43, and 18-fold selectivity for PI3Kγ over the α, β, and δ isoforms, respectively. PI3Kγ inhibitor 4 can be used for the research of airway inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kγ inhibitor 5

Cat. No.: HY-139880

PI3Kγ inhibitor 5 is an inhibitor of phosphoinositide 3-kinase γ **(PI3Kγ)** with an IC_{50} value of 34 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3kδ inhibitor 1

Cat. No.: HY-15288

PI3kδ inhibitor 1 is a potent and selective **PI3Kδ** inhibitor with an IC_{50} of 3.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ-IN-1

Cat. No.: HY-101921

PI3Kδ-IN-1 is a potent, selective, and efficacious **PI3Kδ** inhibitor with an IC_{50} of 1.7 nM.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PI3Kδ-IN-10

Cat. No.: HY-144254

PI3Kδ-IN-10 is a highly potent and orally active **PI3Kδ** inhibitor with IC_{50} of 2 nM. PI3Kδ-IN-10 robustly suppresses the downstream **AKT** pathway to induce subsequent **apoptosis** in hepatocellular carcinoma models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ-IN-11

Cat. No.: HY-143472

PI3Kδ-IN-11 is a highly potent and selective **PI3Kδ** inhibitor with IC_{50} value of 27.5 nM. PI3Kδ-IN-11 dose-dependently blocks the activity of **PI3K/Akt** pathway. PI3Kδ-IN-11 can be used for researching B or T cell-related malignancies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ-IN-5

Cat. No.: HY-122593

PI3Kδ-IN-5 (compound 7n) is a highly potent and selective inhibitor of **PI3Kδ** with an IC_{50} of 0.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ-IN-8

Cat. No.: HY-134472

PI3Kδ-IN-8 is a potent, selective and orally active **PI3Kδ** inhibitor, with an IC_{50} of 3.3 nM. PI3Kδ-IN-8 shows selectivity for PI3Kδ over **PI3Kα**, **PI3Kβ**, and **PI3Kγ** (IC_{50}=377.2, 241.6, 17.9 nM, respectively). PI3Kδ-IN-8 has anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ-IN-9

Cat. No.: HY-142646

PI3Kδ-IN-9 is a selective **PI3Kδ** inhibitor with an IC_{50} value of 3.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ/γ-IN-1

Cat. No.: HY-144993

PI3Kδ/γ-IN-1 is a potent, selective **PI3K-δ/γ** inhibitor for treatment of hematological malignancies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kδ/γ-IN-2

Cat. No.: HY-146789

PI3Kδ/γ-IN-2 is a potent **PI3Kδ** and **PI3Kγ** dual inhibitor with IC_{50}s of 1 nM and 4.3 nM, respectively. PI3Kδ/γ-IN-2 has favorable oral bioavailability. PI3Kδ/γ-IN-2 has potential for battling B-cell malignancies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI4KIIIbeta-IN-9

Cat. No.: HY-19798

PI4KIIIbeta-IN-9 is a potent **PI4KIIIβ** inhibitor with an IC_{50} of 7 nM. PI4KIIIbeta-IN-9 also inhibits **PI3Kδ** and **PI3Kγ** with IC_{50}s of 152 nM and 1046 nM, respectively.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Pictilisib

(GDC-0941)

Cat. No.: HY-50094

Pictilisib (GDC-0941) is a potent inhibitor of **PI3Kα/δ** with an IC_{50} of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pictilisib dimethanesulfonate

(GDC-0941 dimethanesulfonate; GDC-0941 2 MeSO3H salt)

Cat. No.: HY-20180

Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of **PI3Kα/δ** with IC_{50} of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).



Purity: 99.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

PIK-108

Cat. No.: HY-111184

PIK-108 is a non-ATP competitive, allosteric **p110β/p110δ** selective inhibitor.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PIK-293

Cat. No.: HY-13504

PIK-293, an analog of IC87114, is a **PI3K** inhibitor, with IC_{50} values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PIK-294

Cat. No.: HY-10303

PIK-294 is a potent **p110δ**-selective inhibitor with an IC_{50} of 10 nM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PIK-75

Cat. No.: HY-107834

PIK-75 is a reversible **DNA-PK** and **p110α**-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC_{50}s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC_{50}=1.3 μM). PIK-75 induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PIK-75 hydrochloride

Cat. No.: HY-13281

PIK-75 hydrochloride is a reversible **DNA-PK** and **p110α**-selective inhibitor, which inhibits DNA-PK, **p110α** and p110γ with **IC_{50}**s of 2, 5.8 and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α >200-fold more potently than p110β (IC_{50}=1.3 μM). PIK-75 hydrochloride induces **apoptosis**.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PIK-90

Cat. No.: HY-12030

PIK-90 is a **DNA-PK** and **PI3K** inhibitor, which inhibits **p110α**, **p110γ** and **DNA-PK** with **IC_{50}**s of 11, 18 and 13 nM, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

PIK-93

Cat. No.: HY-12046

PIK-93 is the first potent, synthetic **PI4K (PI4KIIIβ)** inhibitor with **IC_{50}** of 19 nM, and also inhibits **PI3Kγ** and **PI3Kα** with **IC_{50}** of 16 nM and 39 nM, respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pilaralisib

(XL-147; SAR245408)

Cat. No.: HY-16526

Pilaralisib (XL147; SAR245408) is a potent and highly selective class I **PI3Ks** inhibitor with **IC_{50}**s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.



Purity: 99.57%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pilaralisib analogue

(XL147 analogue)

Cat. No.: HY-11105

Pilaralisib analogue (XL147 analogue) is a representative and selective **PI3Kα** inhibitor extracted from patent WO2012006552A1, Compound 147 in Table 1.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PIT-1

Cat. No.: HY-103224

PIT-1 is a selective **PIP3** (phosphatidylinositol 3,4,5-trisphosphate) antagonist. PIT-1 inhibits cancer cell survival and induces apoptosis by inhibition of PIP3 dependent PI3K / Akt signaling. PIT-1 exhibits antitumor activity in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKI-179

Cat. No.: HY-11080

PKI-179 is a potent and orally active dual **PI3K/mTOR** inhibitor, with **IC_{50}**s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for **PI3K-α**, **PI3K-β**, **PI3K-γ**, **PI3K-δ** and **mTOR**, respectively. PKI-179 also exhibits activity over **E545K** and **H1047R**, with **IC_{50}**s of 14 nM and 11 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKI-179 hydrochloride

Cat. No.: HY-11080A

PKI-179 hydrochloride is a potent and orally active dual **PI3K/mTOR** inhibitor, with **IC_{50}**s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for **PI3K-α**, **PI3K-β**, **PI3K-γ**, **PI3K-δ** and **mTOR**, respectively.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKI-402

Cat. No.: HY-10683

PKI-402 is a selective, reversible, ATP-competitive inhibitor of **PI3K**, including PI3K-α mutants, and **mTOR** (**IC_{50}**=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Polygalasaponin F

Cat. No.: HY-N0392

Polygalasaponin F, an oleanane-type triterpenoid saponin extracted from Polygala japonica, decreases the release of the inflammatory cytokine tumor necrosis factor a (TNFa).



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

PP30

Cat. No.: HY-15269

PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of **mTOR** with an IC_{50} of 80 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PQR530

Cat. No.: HY-107365

PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-**PI3K/mTORC1/2** inhibitor, with a subnanomolar K_d toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Quercetin

Cat. No.: HY-18085

Quercetin, a natural flavonoid, is a stimulator of recombinant **SIRT1** and also a **PI3K** inhibitor with IC_{50} of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.



Purity: 98.02%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Quercetin dihydrate

Cat. No.: HY-N0146

Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant **SIRT1** and a **PI3K** inhibitor with **IC_{50}s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.**.



Purity: ≥96.0%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 500 mg

Quercetin-13C3

Cat. No.: HY-18085S2

Quercetin-13C3 is the 13C-labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant **SIRT1** and also a **PI3K** inhibitor with IC_{50} of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quercetin-d3

Cat. No.: HY-18085S1

Quercetin-d3 is the deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant **SIRT1** and also a **PI3K** inhibitor with IC_{50} of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Quercetin-d5

Cat. No.: HY-18085S

Quercetin-d5 is a deuterium labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant **SIRT1** and also a **PI3K** inhibitor with IC_{50} of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Recilisib
(ON 01210)

Cat. No.: HY-101625

Recilisib (ON 01210) is a radioprotectant, which can activate **AKT**, **PI3K** activities in cells.



Purity: 98.94%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rigosertib
(ON-01910)

Cat. No.: HY-12037A

Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the **PI3 kinase/Akt** pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle.



Purity: 98.81%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Rigosertib sodium
(ON-01910 sodium)

Cat. No.: HY-12037

Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the **PI3K/Akt** pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle.



Purity: 99.49%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Samotolisib

(LY3023414)

Cat. No.: HY-12513

Samotolisib (LY3023414) potently and selectively inhibits **class I PI3K** isoforms, **DNA-PK**, and **mTORC1/2** with IC_{50}s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively.



Purity: 99.42%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SAR-260301

Cat. No.: HY-15837

SAR-260301 is an orally available and selective **PI3Kβ** inhibitor with an IC_{50} of 23 nM.



Purity: 99.37%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SAR405

Cat. No.: HY-12481

SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PIK3C3) isoform **Vps34** inhibitor (IC_{50}=1.2 nM; K_d=1.5 nM). SAR405 inhibits autophagy induced either by starvation or by mTOR inhibition. Anticancer activity.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Seletalisib

(UCB5857)

Cat. No.: HY-16754

Seletalisib (UCB5857) is potent and selective **PI3Kδ** inhibitor with an IC_{50} of 12 nM.



Purity: 98.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Serabelisib

(MLN1117; INK1117; TAK-117)

Cat. No.: HY-12285

Serabelisib (MLN1117) is a selective **p110α** inhibitor with an IC_{50} of 15 nM.



Purity: 99.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SF1126

Cat. No.: HY-10220

SF1126 is a relevant pan and dual first-in-class **PI3K/BRD4** inhibitor, has antitumor and anti-angiogenic activity.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

SF2523

Cat. No.: HY-101146

SF2523 is a highly selective and potent inhibitor of **PI3K** with IC_{50}s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for **PI3Kα**, **PI3Kγ**, **DNA-PK**, BRD4 and mTOR, respectively.



Purity: 97.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SKI V

Cat. No.: HY-12895

SKI V is a noncompetitive and potent non-lipid **sphingosine kinase (SPHK; SK)** inhibitor with an IC_{50} of 2 μM for GST-hSK. SKI V potently inhibits **PI3K** with an IC_{50} of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P).



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sonolisib

(PX-866)

Cat. No.: HY-N6775

Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of **PI3K** (IC_{50}=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity.



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg

Sophocarpine

Cat. No.: HY-N0103

Sophocarpine is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Sophocarpine monohydrate

Cat. No.: HY-N0103A

Sophocarpine (monohydrate) is one of the significant alkaloid extracted from the traditional herb medicine Sophora flavescens which has many pharmacological properties such as anti-virus, anti-tumor, anti-inflammatory.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SRX3207

Cat. No.: HY-136198

SRX3207 is an orally active and first-in-class dual **Syk/PI3K** inhibitor, with IC_{50} values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Taselisib

(GDC-0032; RG-7604)

Cat. No.: HY-13898

Taselisib (GDC-0032) is a potent **PI3K** inhibitor targets PIK3CA mutations, with K_is of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.



Purity: 99.86%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

TASP0415914

Cat. No.: HY-120438

TASP0415914 is a potent and orally active **PI3Kγ** inhibitor with an IC_{50} of 29 nM. TASP0415914 also shows potent **Akt** inhibitory activities with an IC_{50} of 294 nM. TASP0415914 can be used for inflammatory diseases research.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tenalisib

(RP6530)

Cat. No.: HY-17645

Tenalisib (RP6530) is a novel, potent, and selective **PI3Kδ** and **PI3Kγ** inhibitor with IC_{50} values of 25 and 33 nM, respectively.



Purity: 98.94%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TG 100713

Cat. No.: HY-13514

TG 100713 is an inhibitor of **PI3K**, with IC_{50}s of 24, 50, 165, and 215 nM for **PI3Kδ**, **γ**, **α** and **β** isoforms respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TG100-115

Cat. No.: HY-10111

TG100-115 is a selective **PI3Kγ/PI3Kδ** inhibitor with IC_{50}s of 83 and 235 nM, respectively.



Purity: 99.31%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

TGX-221

Cat. No.: HY-10114

TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the **PI3K p110β** catalytic subunit, used for cancer treatment.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Topoisomerase I/II inhibitor 3

Cat. No.: HY-146504

Topoisomerase I/II inhibitor 3 (compound 7) is a potent **topoisomerase I (Topo I)** and **II (Topo II)** dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce **apoptosis** by inhibiting **PI3K**/Akt/mTOR signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Umbralisib

(TGR-1202; RP5264)

Cat. No.: HY-12279

Umbralisib (TGR-1202) is a novel **PI3Kδ** inhibitor, with IC_{50} and EC_{50} of 22.2 nM and 24.3 nM, respectively; Umbralisib (TGR-1202) is also active against **CK1ε**, with an EC_{50} value of 6.0 μM.



Purity: 98.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Umbralisib hydrochloride

(TGR-1202 hydrochloride; RP5264 hydrochloride) Cat. No.: HY-12279C

Umbralisib hydrochloride (TGR-1202 hydrochloride) is a novel **PI3Kδ** inhibitor, with **IC_{50}** and **EC_{50}** of 22.2 nM and 24.3 nM, respectively; Umbralisib hydrochloride (TGR-1202 hydrochloride) is also active against **CK1ε**, with an **EC_{50}** value of 6.0 μM.



Purity: 98.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Umbralisib R-enantiomer

(TGR-1202 R-enantiomer; RP5264 R-enantiomer) Cat. No.: HY-12279F

Umbralisib R-enantiomer (TGR-1202 R-enantiomer) is a **PI3Kδ** inhibitor, which is the less active enantiomer of TGR-1202.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

Viridin

Cat. No.: HY-N10189

Viridin is a secondary metabolite and naturally occurring furanosteroid. Viridin is potent inhibitor of the lipid kinase **PI3K**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Voxtalisib

(XL765; SAR245409) Cat. No.: HY-15900

Voxtalisib (XL765) is a potent **PI3K** inhibitor, which has a similar activity toward class I PI3K (**IC_{50}**s=39, 113, 9 and 43nM for **p110α**, **p110β**, **p110γ** and **p110δ**, respectively), also inhibits DNA-PK (IC_{50}=150nM) and mTOR (IC_{50}=157nM).



Purity: 99.46%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vps34-IN-1

Cat. No.: HY-12795

Vps34-IN-1 is an inhibitor of **Vps34** extracted from patent WO2012085815A1, compound example 16a, with an **IC_{50}** of 4 nM. Vps34-IN-1 modulates **autophagy**.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vps34-IN-2

Cat. No.: HY-12473

Vps34-IN-2 is a novel, potent and selective inhibitor of **Vps34** with **IC_{50}**s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Vps34-IN-3

Cat. No.: HY-141895

Vps34-IN-3 is a potent, selective, and orally bioavailable **VPS34** kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vps34-IN-4

Cat. No.: HY-123058

Vps34-IN-4 (compound 19) is a potent, selective, and orally active inhibitor of VPS34. Vps34-IN-4 inhibits the autophagy in vivo. Autophagy is a dynamic process that regulates lysosomal-dependent degradation of cellular components.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Vps34-PIK-III

Cat. No.: HY-12794

Vps34-PIK-III is a potent and selective inhibitor of **VPS34** with an **IC_{50}** of 18 nM.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VS-5584

(SB2343) Cat. No.: HY-16585

VS-5584 is a **pan-PI3K/mTOR** kinase inhibitor with **IC_{50}**s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks **mTORC2** as well as **mTORC1**.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Wortmannin

(SL-2052; KY-12420) Cat. No.: HY-10197

Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible **PI3K** inhibitor with an IC_{50} of 3 nM. Wortmannin also blocks **autophagy** formation, and potently inhibits **Polo-like kinase 1 (PLK1)** and **Plk3** with IC_{50}s of 5.8 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

WYE-687

Cat. No.: HY-15271

WYE-687 is an ATP-competitive **mTOR** inhibitor with an IC_{50} of 7 nM. WYE-687 concurrently inhibits activation of **mTORC1** and **mTORC2**. WYE-687 also inhibits **PI3Kα** and **PI3Kγ** with IC_{50}s of 81 nM and 3.11 μM, respectively.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WYE-687 dihydrochloride

Cat. No.: HY-15271A

WYE-687 dihydrochloride is an ATP-competitive **mTOR** inhibitor with an IC_{50} of 7 nM. WYE-687 dihydrochloride concurrently inhibits activation of **mTORC1** and **mTORC2**. WYE-687 also inhibits **PI3Kα** and **PI3Kγ** with IC_{50}s of 81 nM and 3.11 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

YH-306

Cat. No.: HY-120213

YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via **FAK** pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YM-201636

Cat. No.: HY-13228

YM-201636 is a potent and selective **PIKfyve** inhibitor with an IC_{50} of 33 nM. YM-201636 also inhibits p110α with an IC_{50} of 3.3 μM. YM-201636 inhibits **retroviral** replication.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

YS-49

Cat. No.: HY-15477

YS-49 is a **PI3K/Akt** (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits **angiotensin II (Ang II)**-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

YS-49 monohydrate

Cat. No.: HY-15477A

YS-49 (monohydrate) is a **PI3K/Akt** (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits **angiotensin II (Ang II)**-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Zandelisib

(ME-401; PWT-143) Cat. No.: HY-109198

Zandelisib (ME-401) is a **phosphatidylinositol 3-kinase (PI3K)** inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits **p110δ** with an IC_{50} of 3.5 nM. Zandelisib functions as an antineoplastic.



Purity: 98.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZSTK474

Cat. No.: HY-50847

ZSTK474 is an ATP-competitive pan-class I **PI3K** inhibitor with IC_{50}s of16 nM, 44 nM, 4.6 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.



Purity: 99.71%
Clinical Data: Phase 1
Size: 10 mg, 50 mg, 100 mg, 200 mg

α-Linolenic acid

Cat. No.: HY-N0728

α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of **PI3K/Akt** signaling.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 500 mg

α-Linolenic acid-13C18

Cat. No.: HY-N0728S3

α-Linolenic acid-13C18 is the 13C labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of **PI3K/Akt** signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Linolenic acid-d14

Cat. No.: HY-N0728S2

α-Linolenic acid-d14 is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of **PI3K/Akt** signaling.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α-Linolenic acid-d5

Cat. No.: HY-N0728S

α-Linolenic acid-d5 is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of **PI3K/Akt** signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg